惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

美团技术团队
Blog — PlanetScale
Blog — PlanetScale
阮一峰的网络日志
阮一峰的网络日志
M
MIT News - Artificial intelligence
月光博客
月光博客
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
U
Unit 42
博客园_首页
WordPress大学
WordPress大学
H
Hackread – Cybersecurity News, Data Breaches, AI and More
J
Java Code Geeks
F
Fortinet All Blogs
腾讯CDC
罗磊的独立博客
IT之家
IT之家
I
InfoQ
V
V2EX
博客园 - 叶小钗
A
About on SuperTechFans
Y
Y Combinator Blog
C
Check Point Blog
量子位
Martin Fowler
Martin Fowler
Vercel News
Vercel News

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
2026-05-16 · via All Articles on Seeking Alpha

Q1: 2026-05-15 Earnings Summary

EPS of -$0.21 misses by $0.04

 | 

Revenue of

$0.00

beats by $0.00

BioCardia, Inc. (BCDA) Q1 2026 Earnings Call May 15, 2026 4:30 PM EDT

Company Participants

Miranda Benvenuti - Investor Relations Executive
Peter Altman - CEO, President & Director
David McClung - Chief Financial Officer

Conference Call Participants

Laura Suriel

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2026 First Quarter Financial Results and Business Update Conference Call. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately 1 hour after the end of the call.

I would now like to turn the call over to Miranda Peto of BioCardia Investor Relations. Please go ahead, Miranda.

Miranda Benvenuti
Investor Relations Executive

Thank you very much. Good afternoon, and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, President and Chief Executive Officer; and David McClung, the company's Chief Financial Officer.

During this call, management will be making forward-looking statements, including statements that address BioCardia's expectations for future performance and operational results, references to management's intentions, beliefs, projections, outlook, analyses and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products, technologies and obtaining regulatory approvals.

Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors and cautionary statements described in BioCardia's report on Form 10-K filed with the SEC on March 24, 2026. The content of this call contains time-sensitive information that is accurate only as of today, May 15, 2026. Except as required by law, the company disclaims any obligation to publicly update or revise any